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Background: The aberrant expression of CD40, a co-stimulatory receptor found on the antigen-presenting cells, is
involved in the pathogenesis of various degenerative diseases. Our previous study demonstrated that the reduction
of cytosolic phospholipase A2 alpha (cPLA2α) protein overexpression and activation in the spinal cord of a mouse
model of ALS, hmSOD1 G93A, inhibited CD40 upregulation in microglia. The present study was designed to
determine whether cPLA2α has a direct, participatory role in the molecular events leading to CD40 induction.
Methods: Cultures of primary mouse microglia or BV-2 microglia cell line exposed to lipopolysaccharide (LPS) or
interferon gamma (IFNγ) for different periods of time, in order to study the role of cPLA2α in the events leading to
CD40 protein induction.
Results: Addition of LPS or IFNγ caused a significant upregulation of cPLA2α and of CD40, while prevention of
cPLA2α upregulation by a specific oligonucleotide antisense (AS) prevented the induction of CD40, suggesting a
role of cPLA2α in the induction of CD40. Addition of LPS to microglia caused an immediate activation of cPLA2α
detected by its phosphorylated form, while addition of IFNγ induced cPLA2α activation at a later time scale (4 h).
The activation of cPLA2α is mediated by ERK activity. Suppression of cPLA2α activity inhibited superoxide
production by NOX2-NADPH oxidase and activation of NF-κB detected by the phosphorylation of p65 on serine
536 at 15 min by LPS and at 4 h by IFNγ. Inhibition of NOX2 prevented NF-κB activation and CD40 induction but
did not affect cPLA2α activation, suggesting cPLA2α is located upstream to NOX2 and NF-κB. The activation of
cPLA2 by LPS was mediated by both adaptor proteins downstream to LPS receptor; TRIF and MyD88, while the
activation of cPLA2α by IFNγ was mediated by the secreted TNF-α at 4 h. The early activation of STAT1α (detected
by phospho-serine727 and phoshpo-tyrosine701) by IFNγ and the late activation of STAT1α by LPS were not
affected in the presence of cPLA2α inhibitors, indicating that STAT1α is not under cPLA2α regulation.
Conclusions: Our results show for the first time that cPLA2 upregulates CD40 protein expression induced by either LPS
or IFNγ, and this regulatory effect is mediated via the activation of NOX2-NADPH oxidase and NF-κB. Cumulatively, our
results indicate that cPLA2α may serve as a pivotal amplifier of the inflammatory response in the CNS.
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The co-stimulatory receptor, CD40 molecule, is a 50-
kDa type I member of the tumor necrosis factor receptor
superfamily that is widely expressed by the various im-
mune and non-immune cells [1–7]. The interaction be-
tween CD40 and its ligand, CD40L (CD154), is one of
multiple signals necessary for a productive immune re-
sponse [8–10]. The CD40-CD154 interaction promotes a
wide spectrum of molecular and cellular processes in-
cluding, immunoglobulin class switching, cell differenti-
ation and maturation, B-cell growth, and expression of
other co-stimulatory molecules such as MHC class II,
ICAM-1, VCAM-1, E-selectin, LFA-3, B7.1, and B7.2)
[11, 12]. In addition, CD40-CD154 interaction induces
the production of cytotoxic radicals and of various pro-
inflammatory cytokines (TNF-α, IL6, IL-8, and IL-12)
and chemokines (CCL-2) [13, 14].
In the central nervous system (CNS), the microglial
cells are constantly in motion, surveying their environ-
ment to protect the nervous system acting as debris
scavengers, killers of pathogens, and regulators of innate
and adaptive immune responses. The microglia cells ex-
press the key surface molecules for antigen presentation
(CD40, MHC-II, and B7); therefore, they are considered
the most potent endogenous antigen-presenting cells in
the CNS [15]. In a healthy nervous system, microglia
constitutively expresses CD40 at a low level, which is en-
hanced under inflammatory conditions. Several studies
show that the aberrant expression of CD40 is involved
in the initiation and maintenance of various neurode-
generative diseases including multiple sclerosis, Alzhei-
mer’s disease, HIV-1-associated dementia and cerebral
ischemia [16–20], and other diseases as rheumatoid
arthritis and atherosclerosis [18, 21, 22]. Blockade of
CD40-CD40L signaling has been shown to provide a sig-
nificant beneficial effect in a number of animal models
of neurological human diseases [1, 18, 23–28].
Previous findings suggested that cPLA2α plays an im-
portant role in inflammation. cPLA2α specifically hydro-
lyzes phospholipids containing arachidonic acid at the
sn-2 position [29, 30] and is generally thought to be the
rate-limiting step in the generation of eicosanoids and
platelet activating factor. These lipid mediators play crit-
ical roles in the initiation and modulation of inflamma-
tion and oxidative stress. cPLA2α is ubiquitous in the
brain cells and is essential for their physiological regula-
tion. However, elevated cPLA2α expression and activity
were detected in the inflammatory sites in a vast array of
inflammatory diseases [31], including neurodegenerative
diseases such as Alzheimer’s disease, multiple sclerosis,
and amyotrophic lateral sclerosis (ALS) [32–35]. Our
previous study [36] in a mouse model of ALS, hmSOD1
G93A, demonstrated that the blunting cPLA2α protein
expression and inhibition of its activity inhibitedmicroglial-CD40 upregulation. This inhibitory effect
could be a result of a direct regulatory role of cPLA2α
on CD40 inductive process or an indirect effect due to
damping of inflammation. The present study was de-
signed to determine whether cPLA2α has a direct role in
the events leading to CD40 protein induction. To this
aim, we used mouse microglia cultures and two different
stimuli, LPS and IFNγ that have been reported to induce
CD40 upregulation. The signal transduction events lead-
ing to CD40 upregulation by both stimuli have been
studied, and it was reported that they include two tran-
scription factors NF-κB and STAT1α that are activated





buffered saline (PBS) Dulbecco’s Modified Eagle’s
Medium (DMEM), Hanks’ Balanced Salts Solution
(HBSS), fetal bovine serum (FBS), HEPES, sodium pyru-
vate, Dulbecco’s Modified Eagle’s/F12 (HAM) medium
(DMEM/F12) were from Beth Ha-Emek, Biological In-
dustries, Israel.
Sodium azide, trypan blue, p-nitrophenylphosphate,
phenylmethylsulfonyl fluoride, leupeptin, benzamidine,
aprotinin, DMSO, Tween 20, Tris, 4,6-diamidino-2-
phenylindole (DAPI), bovine serum albumin (BSA),
Trypsin-EDTA, dihyroethidium (DHE), lipopolysaccharide
(LPS), Skim Milk Powder, Poly-L-lysine, horseradish
peroxidase (HRP), 1,2-Dioleoyl-sn-glycerol, Triton X-100,
β-mercaptoethanol, Percoll, non-essential amino-acids,
Diphenyliodonium chloride (DPI) were from Sigma Israel,
Rehovot, Israel. Fetal calf serum was from GE Healthcare
Life Sciences HyClone Laboratories, Inc., Logan Utah,
USA. ECL detection kit for the immunoblot analysis was
from PerkinElmer, MA, USA. Pyrrophenone was from
Cayman Chemical, Michigan, USA. TNF-α-neutralizing
antibody and U0126 (MEK1/2 inhibitor) were from Cell
Signaling Technology, Danvers, MA, USA. Interleukin
(IL)-4, IL-10, TNF-α, IFN-γ were from PeproTech Asia,
NJ, USA.
Primary microglial cell culture
Microglia were isolated from the brains of mice C57BL
1-day-old pups as previously described [40] with minor
modifications. Briefly, the pups were decapitated and the
brains were taken out. The tissues were digested by in-
cubation with an enzymatic solution containing papain
(116 mM NaCl, 5.4 mM KCl, 26 mM NaHCO3, 1 mM
NaH2PO4, 1.5 mM CaCl2, 1 mM MgSO4, 0.5 mM
EDTA, 25 mM glucose, 1 mM cysteine, and 20 U/ml pa-
pain) for 60 min at 37 °C, 5% CO2. The enzymatic solu-
tion was quenched with 20% FBS in HBSS and
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cedure was performed by treating the brain tissues with
0.5 mg/ml DNase-I (Worthington Biochemical Corp.,
NJ, USA) for 5 min and gently passing it through a fire-
polished Pasteur pipettes several times. Then, the
digested tissues were filtered through a 70 micron cell
strainer (Corning, NY, USA) and centrifuged at 200g for
4 min. The pellet was resuspended in 20% isotonic per-
coll in HBSS. Fresh HBSS was carefully added and then
the tubes were centrifuged at ×200g for 20 min with
slow acceleration and no brakes. The pellet containing
the mixed glial cells were washed with HBSS, centri-
fuged at ×200g for 4 min and then suspended in
DMEM-F12 medium (10% FCS, 1% non-essential
amino-acids, 11.4 μm β-mercaptoethanol, 10 mM
HEPES, 1 mM sodium pyruvate 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and
12.5 U/ml nystatin). The cells were seeded into Poly-L-
lysine coated flasks and kept at 37 °C in a humidified at-
mosphere of 5% CO2. The growth medium was replaced
with a fresh after 4 days. After two weeks, the microglial
cells were separated from the astroglial cell monolayer
by shaking the flasks for 1 h at 120 rpm on a rotator
shaker and subjected to mild trypsinization with DMEM
containing 0.25% Trypsin-EDTA (1:3) for about 90 min
at 37 °C and then exchange with fresh DMEM. Then,
the isolated microglial cultures were treated with 0.25%
Trypsin for approximately 15 min at 37 °C and carefully
detached. The cells were suspended with DMEM-F12
(containing 2% FBS 2 mM glutamine, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, and 12.5 U/ml Nystatin)
and cultured (6 × 105 cells/ml) in 24 wells on cover-slips
coated with Poly-L-lysine at 37 °C in a humidified at-
mosphere of 5% CO2 for a week before the experiment.
The purity of microglial cell preparations was confirmed
by testing their immunoreactivity to the Iba-1 (Wako
Chemicals, Richmond, VA, USA) marker.
Cell cultures
BV2 immortalized murine microglial cell line was a kind
gift from Prof. Rosario Donato (Department of Biochem-
ical Sciences, University of Perugia, Italy). The cells were
maintained in DMEM containing 5% FBS 2 mM L-glu-
tamine, 100u/ml penicillin, 100 μg/ml streptomycin, and
12.5 U/ml Nystatin at 37 °C and 5% CO2 until they
reached confluence. The cells (3.5 × 105 cells/ml) were
suspended in DMEM containing 2% FBS, 2 mM L-glu-
tamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 12.5 U/ml Nystatin and seeded in plates of 24 or 6
wells at 37 °C in a humidified atmosphere of 5% CO2.
Flow cytometry
The microglial cells were suspended in PBS and counted
by Trypan Blue. The cells were pre-incubated with ratanti-mouse Fc Blocker (BD Pharmingen, San Jose, CA)
at 4 °C for 10 min. For detection of CD40, the cells were
incubated with PE anti-mouse CD40 (BioLegend, San
Diego, CA) for 2 h on ice in the presence of Fc Blocker.
Next, the cells were washed three times with PBS and
subjected to fluorescence-activated cell sorter (FACS FC
500, Switzerland, Beckman Coulter) analysis. The me-
dian (median of fluorescence intensity) was calculated by
subtracting the non-specific fluorescence.Immunofluorescence analysis
Microglia were suspended in DMEM (2% FBS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 12.5 U/ml Nystatin) and seeded on cover slips. The
cells were fixed with ice-cold methanol for 3 min and
then washed with HBSS. For immunofluorescence detec-
tion, the fixed microglial cells were incubated with the
first antibody 1:50 in 5% BSA/PBS (anti cPLA2α (Santa
Cruz Biotechnology, CA, USA), anti CD40 (Serotec,
Cambridge, UK), anti CD206 (R&D Systems, Minneap-
olis, USA) Serotec, Oxfordshire, UK) for 90 min at room
temperature. The cells were washed three times in HBSS
and incubated with Cy3 anti-rabbit, DyLight anti-rabbit,
and Cy3 anti-goat (1:50 in 5% BSA/PBS; Jackson Immu-
noResearch Laboratories, Inc., PA, USA) for 60 min at
room temperature. The cells were washed three times in
HBSS, and the nuclei were stained with DAPI. Then,
final wash was performed and the cells were taken to
fluorescence microscope analysis (Olympus, BX60,
Hamburg, Germany).Intracellular superoxide anion assay
O2
− production was measured using dihyroethidium
(DHE). The cells were incubated in a 24-well plate on
cover slips for 24 h at 37 °C. The next day the medium
was replaced with heated HBSS containing 10 μm DHE,
and the cells were incubated for 45 min at 37 °C. Then,
the cells were stimulated with IFN-γ or LPS for 15 min.
Then, the cells were stained with DAPI, washed, and
fixed with ice-cold methanol for 3 min. the fluorescence
intensity was measured by fluorescence microscope
(Olympus, BX60, Hamburg, Germany).Inhibition of cPLA2α expression using antisense
oligonucleotides
An oligodeoxy-nucleotide antisense (tcaaaggtctcattccaca)
and its corresponding sense with phosphorothioate modi-
fications on the last three bases at both 5′ and 3′ ends
were used as described in our previous article [35]. The
specificity to cPLA2α was analyzed by blast search pro-
gram and was demonstrated in our previous study [31].
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Microglial cell lysates were prepared using lysis buffer
containing: 2% Triton X-100, 50 mM HEPES (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% gly-
cerol, 10 μm MgCl2, 10 μg/ml leupeptin, 1 mM phenyl-
methylsulphonylfluoride, 10 μg/ml aprotonin, 1 mM
benzamidine, 20 mM para-nitrophenyl phosphate, 5 mM
sodium orthovanadate, 10 mM sodium fluoride, and
50 mM β-glycerophosphate). Cell lysates were analyzed
by SDS-PAGE on 9% gels. The amount of protein in
each sample was quantified with the Pierce BCA Pro-
teins Assay using BSA standards. The resolved proteins
were transferred to nitrocellulose and blocked in 5%
BSA in TBS-T (10 mM Tris, 135 mM NaCl, pH 7.4,
0.1% Tween 20). The blots were incubated overnight at
4 °C with primary antibodies (anti-cPLA2α and anti-
phospho-(serine-505)-cPLA2α from Sigma, anti-NF-κB
p65, anti-phospho-(serine-536)-NF-κB p65, anti phopho-
p44/42 ERK1/2 (Thr202/Tyr204), anti-p44/42 ERK1/2,
anti-STAT1α, anti-phospho-(serine-727)-STAT1α, anti-
phospho-(Thr-701)-STAT1α from Cell Signaling, MA,
USA; washed and incubated with peroxidase-conjugated
secondary antibodies (Amersham Pharmacia Biotech,
NJ, USA) for 1.5 h at room temperature. Detection of
immunoreactive bands was carried out using enhanced
chemiluminescence. Changes in protein expression or
phosphorylation were quantified by densitometry using
ImageJ program. The intensity of each band was divided
by the intensity of each total protein band and expressed
as arbitrary units. The quantitative measurements are
adequate to determine the changes of each protein in
the same immunoblot.
Separation of plasma membranes and
immunoprecipitation
Plasma membranes were separated as described before
([41]). Cell 108/ml suspended in relaxation buffer
(100 mM KCl, 3 mM NaCl, 3.5 mM MgCl2, 1.25 mM
EGTA, 1 mM ATP, 10 mM PIPES, pH7.4) containing
1 mM PMSF and 100 μm leupeptin at 4 °C and soni-
cated , resulting in 95% cell breakage. After centrifuga-
tion (5 min; ×15,600g) to remove the granules, nuclei,
and unbroken cells, the supernatant was centrifuge in a
Beckman Airfuge (Beckman Instrument, Fulletron, CA)
30 min; ×134,000g to obtain cell membrane pellet and
cytosol supernatant. The membranes were suspended at
109 cell equivalent/ml in 0.34 sucrose/half-strength re-
laxation buffer. The microglial cell membranes subjected
to immunoprecipitation with goat anti-serum raised
against recombinant p47phox (gift from Dr. T Leto,
NIAID, NIH, Bethesda, USA). Immunoprecipitation was
at a final volume of 0.5 ml at 4 °C. Recombinant protein
A–Sepharose beads (Zymed Laboratories Inc., CA, USA)
were added to each sample, and the samples weretumbled end-over-end for 1 h. The beads were then
washed six times with lysis buffer boiled in lamely buffer
and subjected to SDS-PAGE analysis.
TNF-a detection–using mouse TNF-α high sensitivity
ELISA, eBioscience, Vienna, Austria.
Statistical analysis
Significant differences between the parameters evaluated
were determined by ANOVA using GraphPad Prism 5
(GraphPad Software Inc., San Diego, CA, USA) followed
by multiple comparisons Bonferroni post hoc correction.
p value less than 0.05 were considered statistically
significant.
Results
cPLA2α upregulation regulates the overexpression of
CD40 in microglia
Addition of 50 ng/ml LPS or 10 ng/ml IFNγ to BV-2
microglia cell line for 24 h caused a significant (p <
0.0001) elevation of and cPLA2α of CD40 protein ex-
pression, as shown in the double-immunofluorescence
staining analysis (Fig. 1a, b). To determine whether
cPLA2α upregulation is involved in the induction of
CD40 by either LPS or IFNγ, cPLA2α upregulation was
prevented by a specific antisense oligo-deoxy-nucleotide
against cPLA2α (AS). As shown in Fig. 1a, b, impeding
cPLA2α upregulation by addition of 4 μm AS 24 h prior
to addition of LPS or of IFNγ prevented CD40 protein
induction. Incubation with the corresponding sense that
had no effect on the elevation of cPLA2α protein expres-
sion by either of the inducers did not affect the elevation
of CD40 protein expression. To further support these re-
sults, the reduction of both cPLA2α and CD40 in the
presence of AS was validated by western blot analysis
(Fig. 1c, d). Similar results were obtained in primary
mouse microglia cultures. As shown in the immuno-
fluorescence staining (Fig. 1e, f ) and western blot ana-
lysis (Fig. 1g, h), preventing cPLA2α upregulation
prevented the elevated CD40 protein expression induced
by LPS or IFNγ. BV-2 is an immortalized mouse micro-
glia cell line that is reported to share many characteris-
tics with primary microglia [42]. Since the BV-2 cells act
similarly to primary microglia cultures, they were used
to study the role of cPLA2α in the regulation of CD40
upregulation by either LPS or IFNγ.
To study whether cPLA2α affect microglia induction
towards M2 phenotype, the BV-2 cells were cultured
with 20 ng/ml IL4 + 20 ng/ml IL10 for 24 h. IL4 + IL10
caused a significant (p< 0.0001) elevation of CD206
(Fig. 2a). Pre-incubated of the BV-2 cells with AS or the
corresponding sense for 24 h prior to addition of IL4 +
IL10 for 24 h did not affect the elevated expression of
CD206. Similar results were obtained with respect to the
induction of arginase 1, another marker of M2 microglia;
Fig. 1 (See legend on next page.)
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Fig. 1 Elevated CD40 expression by LPS or IFNγ in the BV-2 and primary microglia cells is regulated by cPLA2α. A representative double-
immunofluorescence staining of cPLA2α (green) and CD40 (red) in unstimulated or stimulated microglia by LPS or IFNγ in the absence or
presence of AS or sense (SE). DAPI staining shows cell nuclei. The BV-2 cells were treated with (a) 50 ng/ml LPS or (b) 10 ng/ml IFNγ for
24 h. The mouse primary microglia cells were treated with (e) 50 ng/ml LPS or (f) 25 ng/ml IFNγ for 48 h. Scale bars = 50 μm. Four
micrometer AS or the corresponding sense (SE) were added to the cultures 24 h before addition of the stimuli. The intensity of CD40 or
cPLA2α were quantitated for the cell and expressed in the bar graph as arbitrary units. A representaive immunoblot analysis of cPLA2α
and CD40 for the BV-2 microglia cells (c, d) and primary mouse microglia (g, h) treated as (a), (b), (e), and (f). The intensity of each
cPLA2α or CD40 band after quantification by densitometry was divided by the intensity of each calreticulin (Calre) band and expressed as
arbitrary units. The bar graphs are the mean ± SE from three independent experiments. (***p < 0.0001)
Malada-Edelstein et al. Journal of Neuroinflammation  (2017) 14:33 Page 6 of 16the presence of AS or sense did not affect the elevated
expression of arginase 1 induced by IL4 + IL10 detected
by immunoblot analysis (Fig. 2b).
The location of cPLA2α in the signal transduction leading
to CD40 upregulation by LPS
Next, we aimed to determine the location of cPLA2α in
the suggested signal transduction pathways induced by
either LPS or IFNγ [37–39]. We first focused on the sig-
naling induced by LPS and analyzed the time dependent
of cPLA2α activation determined by the appearance of
its phosphorylated form on serine 505 in BV-2 cells ly-
sates. As shown in Fig. 3a, a significant (p< 0.0001) tran-
sient activation was detected at 15 min after addition of
50 ng/ml LPS to the BV-2 cells. This phosphorylation
was prevented in the presence of 2 μm of pyrrophenone
added 60 min before activation (Fig. 3b). Since we have
previously reported that cPLA2α activity regulatesFig. 2 cPLA2α is not involved in the induction of the BV-2 cells toward
immunofluorescence staining of cPLA2α (green) and CD206 (red) in the
(20 ng/ml) for 24 h in the absence or presence of AS or SE. DAPI stain
CD206 or cPLA2α were quantitated and expressed in the bar graph as
independent experiments. b A representative immunoblot analysis of a
intensity of each Arg1 band after quantification by densitometry was d
arbitrary units. The bar graphs are the mean ± SE from three independeNOX2-NADPH oxidase activity in the phagocytic cells
including primary rat microglia [40], we studied whether
under LPS stimulation the oxidase is also regulated by
cPLA2α. Addition of the oxidase inhibitor, 5 μm DPI,
prior to LPS added for 15 min did not affect the activa-
tion of cPLA2α (Fig. 3b) while addition of 4 μm AS for
24 h or pyrrophenone for 60 min prior to addition of
LPS for 15 min caused a significant (p < 0.0001) inhib-
ition of superoxide production as measured by DHE re-
duction, similar to that caused by the presence of a
specific inhibitor of the oxidase, 200 μm apocynin
(Fig. 3c). Pre-incubation of the BV-2 cells with 4 μm of
the corresponding sense had no effect on superoxide
production. These results indicate that cPLA2α activity
regulates NOX2-NADPH oxidase activity in BV-2
microglia stimulated by LPS. The immunoprecipitation
of the cytosolic subunit of NOX2-NADPH oxidase with
the phosphorylated form of cPLA2α in the membranes M2 phenotype induced by IL-4 + IL-10. A representative double-
unstimulated or stimulated BV-2 cells with IL-4 (20 ng/ml) + IL-10
ing shows cell nuclei. Scale bars = 100 μm. a The intensity of
arbitrary units. The bar graphs are the mean ± SE from three
rginase 1 protein expression in the cells treated as in a. The
ivided by the intensity of each calreticulin band and expressed as
nt experiments. (***p < 0.0001, n.s. not significant)
Fig. 3 (See legend on next page.)
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Fig. 3 cPLA2α activates NFκB through activation of NOX2-NADPH oxidase in the BV-2 microglia cells under LPS stimulation. a A representative
immunoblot analysis of the kinetics of cPLA2α phosphorylation induced by 50 ng/ml LPS, out of three independent experiments. The intensity of
each phosphorylated cPLA2α (p-cPLA2α Ser-505) band after quantification by densitometry was divided by the intensity of each cPLA2α band and
expressed as arbitrary units. The bar graphs are the mean ± SE from three independent experiments. b The BV-2 cells were treated with 2 μm
pyrrophenone (Pyrro) or 5 μm DPI for 60 min before stimulation with 50 ng/ml LPS for 15 min. The intensity of phosphorylated cPLA2α was
quantitated by densitometry as described in (a). The bar graphs are the mean ± SE from three independent experiments. c The effect of cPLA2α
inhibition on superoxide production in the unstimulated or stimulated BV-2 cells with 50 ng/ml LPS for 15 min was detected by DHE reduction.
Two micrometer pyropheonoe (Pyrro) or 200 μm apocynin (used as a positive control) were added to the cells 60 min before stimulation with
LPS. AS or sense were added 24 h prior to addition of LPS. DAPI staining shows cell nuclei. Scale bars large = 50 μm, insert = 20 μm. The intensity
of reduced DHE was quantitated and expressed in the bar graph as arbitrary units. The bar graphs are the mean ± SE from three independent
experiments. d Immunoprecipitation of p47phox and phoshpo cPLA2α (pcPLA2α) in the membrane fraction of unstimulated microglia and
stimulated with LPS for 15 min. Shown a representative immunoblot of three experiments. e Addition of 10 μM arachidonic acid together with
LPS to cells pretreated for 24 h with antisense against cPLA2α restored the expression of CD40 protein. Shown a representative immunofluorescence
staining of CD40. DAPI staining shows cell nuclei. The intensity of CD40 was quantitated for the cell and expressed in the bar graph as arbitrary units.
Scale bars= 50 μm. The bar graph is the mean ± SE from three independent experiments. (***p < 0.0001). f FACS analysis of CD40 protein expression in
the unstimulated or stimulated BV-2 cells with 50 ng/ml LPS for 24 h in the absence or presence of 2 μm pyrrophenone or 5 μm DPI (added to the
cells 60 min before stimulation with LPS). The bar graphs are the X-median ± SE from five independent experiments. g A representative immunoblot
analysis of NF-κB p-65 phosphorylation (p-NFκB p-65 Ser-536) in unstimulated or stimulated BV-2 microglia by 50 ng/ml LPS for 15 min in the absence
or presence of 2 μm pyrrophenone or 5 μm DPI. The intensity of each phosphorylated NF-κB p-65 band after quantification by densitometry was
divided by the intensity of each NFκB p-65 band and expressed as arbitrary units. The bar graphs are the mean ± SE from three independent
experiments. h A representative immunoblot analysis of phoshpo cPLA2α and phospho NF-κB p-65 subunit and phosspho ERK1/2 in unstimulated or
stimulated BV-2 microglia by 50 ng/ml LPS for 15 min in the absence or presence of 5 μM OU126. The bar graphs are the mean ± SE of the intensity of
the quantitated phosphorylated forms divided by the non-phophorylated forms of three independent experiments. i The involvement of TRIF and
MyD88 pathways in activation of cPLA2α in the signaling leading to CD40 upregualtion. The BV-2 cells were incubated with TRIF or MyD88 peptide
inhibitors for 60 min before stimulation with 50 ng/ml LPS for 15 min. A representative immunoblot analysis of cPLA2α activity, out of three independ-
ent experiments is presented. The intensity of phosphorylated cPLA2α (p-cPLA2α Ser-505) was quantitated by densitometry as described in A. j Shown
is a representative immunofluorescence analysis of CD40 protein expression in the cells treated as in i. DAPI staining shows cell nuclei. Scale bars =
50 μm. The intensity of cPLA2α and of CD40 was quantitated and expressed in the bar graph as arbitrary units. The bar graph is the mean ± SE from
three independent experiments. (***p < 0.0001,**p < 0.001, n.s. not significant)
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the role of cPLA2α in the regulation of the oxidase (3D).
Our previous studies demonstrated that arachidonic acid
restored the inhibited NOX2-NADPH oxidase activity in
the absence of cPLA2α activity [43]. In line with our pre-
vious results, addition of arachidonic acid to the stimu-
lated cells in the presence of antisense against cPLA2α
restored the expression of CD40 (Fig. 3e). To further
support that the NOX2-NADPH oxidase is located in
the signal events leading to CD40 upregulation by LPS,
the effect of its inhibition was studied on CD40 expres-
sion. The presence of a specific inhibitor of NOX2-
NADPH oxidase activity (200 μm apocynin) prevented
the elevation of CD40 protein expression induced by
LPS, as determined by FACS analysis, (Fig. 3f ) similar to
the effect caused by the presence of the inhibitor of
cPLA2α activity, pyrrophenone. The results indicate that
the NOX2-NADPH oxidase activity participates in the
signal transduction pathway leading to CD40 induction
by LPS and is located downstream to cPLA2α. As shown
in Fig. 3g, addition of LPS for 15 min caused activation
of NFκB, detected by the phosphorylation of its p65 sub-
unit on serine 536. This phosphorylation was similarly
reduced by inhibition of cPLA2α or NOX2-NADPH oxi-
dase activity by the presence of either pyrrophenone or
DPI, respectively. The presence of a specific inhibitor of
MEK1/2 activation, U0126, caused inhibition of ERK1/2,cPLA2α, and NFκB activation induced by LPS as de-
tected by their phosphorylated forms (Fig. 3h). Taken to-
gether, these results suggest that early after the addition
of LPS to the BV-2 cells, ERK activates cPLA2α that in
turn activates the assembled NOX2-NADPH oxidase
that mediates the activation of NF-κB.
Next, we determined whether MyD88- or TRIF- path-
ways in the signal events induced by LPS are capable of
activating cPLA2α. We used specific peptide inhibitors
for either MyD88 signaling by inhibiting its homodimer-
ization or TRIF signaling by interfering with TLR-TRIF
interaction. As shown in the immunoblot, each peptide
inhibitor inhibited the activation of cPLA2α detected by
its phosphorylated form induced by LPS, to the levels
detected in the unstimulated cells (Fig. 3i). Moreover, ei-
ther of the inhibitors totally prevented the induction of
CD40 induced by LPS, suggesting that both pathways
participate in cPLA2α activation and in CD40 upregula-
tion (Fig. 3j).
Since activation of STAT1α was reported to signal the
induction of CD40 by LPS [39], we studied whether
STAT1α activation is dependent on cPLA2α activity. Kin-
etics analysis of STAT1α activation detected by its phos-
phorylation revealed that significant phosphorylation of
STAT1α on tyrosine 701 (Fig. 4a) and on serine 727
(Fig. 4b) was detected at 4 h of stimulation with LPS. Nei-
ther tyrosine 701 nor serine 727 phosphorylation induced
Fig. 4 STAT1α activation is not under regulation of cPLA2α or NOX2-NADPH oxidase in the BV-2 microglia cells under LPS stimulation. A represen-
tative immunoblot analysis of the kinetics of STAT1α phosphorylation on (a) tyrosine 701 or (b) serine 727 induced with 50 ng/ml LPS. A repre-
sentative immunoblot analysis of STAT1α phosphorylation on (c) tyrosine 701 or on (d) serine 727 in unstimulated or stimulated with 50 ng/ml
LPS for 4 h in the absence or presence of 2 μm pyropheonoe (Pyrro) or 5 μm DPI added to the cells 1 h before stimulation. The intensity of each
phosphorylated STAT1α (p-STAT1α) band after quantification by densitometry was divided by the intensity of each STAT1α band and expressed
as arbitrary units. The Bar graphs are the mean ± SE from three experiments (***p < 0.0001, n.s. not significant)
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inhibitor, pyrrophenone, or the presence of the NOX2-
NADPH oxidase inhibitor, DPI (Fig. 4c, d), suggesting that
STAT1α is not under cPLA2α regulation in the signal cas-
cade leading to CD40 induction by LPS in the BV-2 cells.
The location of cPLA2α in the signal transduction leading
to CD40 upregulation by IFNγ
To determine the location of cPLA2α in the signal trans-
duction events leading to CD40 protein induction by
IFNγ, we first studied the time-dependent activation of
cPLA2α. As shown in Fig. 5a, a significant (p < 0.0001)
cPLA2α activation detected by its phosphorylation on
serine 505 appeared at 240 min of stimulation with
10 ng/ml IFNγ in BV-2 cell lysates. This phosphorylation
was prevented in the presence of 2 μm pyrrophenone
but not by the presence of 5 μm DPI (Fig. 5b), suggest-
ing that the NOX2-NADPH oxidase is downstream to
cPLA2α. Inhibition of cPLA2α activity by addition of ei-
ther AS for 24 h or pyrrophenone for 60 min prior to
stimulation by IFNγ for 4 h caused inhibition of NOX2-
NADPH oxidase activity detected by DHE reduction that
was similar to that achieved in the presence of 200 μm
apocynin (Fig. 5c), while the presence of sense had no
effect. The immunoprecipitation of NOX2-NADPH oxi-
dase cytosolic subunit p47phox with phopho-cPLA2α in
the membrane fraction of the activated mircroglia cellsat 4 h further support the role of cPLA2α in regulating
the oxidase activity (Fig. 5d). Addition of arachidonic
acid to the IFNγ stimulated cells in the presence of anti-
sense against cPLA2α restored the expression of CD40
(Fig. 5e). The presence of DPI or pyrrophenone signifi-
cantly inhibited the induction of CD40 as shown by
FACS analysis (Fig. 5f ). These results suggest that
NOX2-NADPH oxidase is downstream to cPLA2α in the
signal transduction pathway leading to CD40 upregula-
tion induced by IFNγ. Inhibition of cPLA2α or NOX2-
NADPH oxidase by the presence of either pyrrophenone
or DPI inhibited NF-κB activity detected by the phos-
phorylation of its p65 subunit on serine 536 at 4 h of
stimulation with IFNγ (Fig. 5g), suggesting that NF-κB is
downstream to cPLA2α and NOX2-NADPH oxidase.
The presence of a specific inhibitor of MEK1/2 activa-
tion, U0126, caused inhibition of ERK1/2, cPLA2α, and
NF-κB activation at 4 h of induction by IFNγ as detected
by their phosphorylated forms (Fig. 5h).
It was reported that TNF-α is secreted from macro-
phages and microglia after 4 h of stimulation [37] and
has an autocrine effect on the cells. To determine
whether the activation cPLA2α is mediated by endogen-
ous release of TNF-α, we first studied the time-
dependent activation of cPLA2α by TNF-α. As shown in
Fig. 6a, TNF-α caused a rapid and transient activation of
cPLA2α that was similar to that induced by IFNγ for
Fig. 5 (See legend on next page.)
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Fig. 5 cPLA2α activates NF-κB through activation of NOX2-NADPH oxidase in the BV-2 microglia cells under IFNγ stimulation. a A representative
immunoblot analysis of the kinetics of cPLA2α phosphorylation induced by 10 ng/ml IFNγ, out of three independent experiments. The intensity of
phosphorylated cPLA2α (p-cPLA2α Ser-505) was quantitated by densitometry as described in Fig. 3a. b The BV-2 microglia cells were treated with
2 μm pyrrophenone (Pyrro) or 5 μm DPI for 1 h before stimulation with 10 ng/ml IFNγ for 4 h. Phosphorylated cPLA2α (p-cPLA2α Ser-505)
intensity was quantitated by densitometry as described in Fig. 3a. The bar graphs are the mean ± SE from three independent experiments. c The
effect of cPLA2α inhibition on superoxide production in the unstimulated or stimulated BV-2 cells with 10 ng/ml IFNγ for 4 h detected by DHE
reduction. Two micrometer pyropheonoe (Pyrro) or 200 μm apocynin (used as a positive control) were added to the cells 60 min before stimulation
with IFNγ for 4 h. AS or sense (SE) were added 24 h prior to addition of IFNγ. DAPI staining shows cell nuclei. The intensity of reduced DHE was
quantitated and expressed in the bar graph as arbitrary units. Scale bars large = 50 μm, insert = 20 μm. The bar graphs are the mean ± SE from three
independent experiments. d Immunoprecipitation of p47phox and phoshpo cPLA2α (pcPLA2α) in the membrane fraction of unstimulated microglia and
stimulated with IFNγ for 4 h. Shown a representative immunoblot of three experiments. e Addition of 10 μM arachidonic acid togeher with IFNγ to
the cells pre-treated for 24 h with antisense against cPLA2α restored the expression of CD40 protein. Shown a representative immunofluorescence
staining of CD40. DAPI staining shows cell nuclei. The intensity of CD40 was quantitated for the cell and expressed in the bar graph as arbitrary units.
Scale bars= 50 μm. f FACS analysis of CD40 protein expression in the unstimulated or stimulated BV-2 cells with10 ng/ml IFNγ for 24 h in the absence
or presence of 2 μm pyrrophenone (Pyrro) or 5 μm DPI added to the cells 1 h before stimulation. The bar graphs are the X-median ± SE from five
independent experiments. g A representative immunoblot analysis of phosphorylated NF-κB p65 (p-NFκB p-p65(Ser-536) in unstimulated or stimulated
BV-2 microglia by 10 ng/ml IFNγ for 4 h in the absence or presence of 2 μm pyrrophenone (Pyrro) or 5 μm DPI. The intensity of each p-NFκB p-
p65(Ser-536) band after quantification as described in Fig. 3g. The bar graphs are the mean ± SE from three independent experiments. h
A representative immunoblot analysis of phoshpo cPLA2α and phospho NF-κB p-65 subunit and phosspho ERK1/2 in unstimulated or
stimulated BV-2 microglia by 10 ng/ml IFNγ for 4 h in the absence or presence of 5 μM OU126. The bar graphs are the mean ± SE of the
intensity of the quantitated phosphorylated forms divided by the non-phophorylated forms of three independent
experiments. (***p < 0.0001)
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microglia stimulated by IFNγ (Table 1). TNF-α could be
significantly detected in the supernatant of microglia
cultures for 4 h with IFNγ. The dose-dependent activa-
tion of cPLA2α by TNF-α showed that cPLA2α was sig-
nificantly (p < 0.01) activated by 0.5 ng/ml TNF-α, while
2 and 10 ng/ml were yet more significant (p < 0.0001)
with a similar effect (Fig. 6b). A similar dose-dependent
effect was detected for NF-kB activated by TNF-α
(Fig. 6c). To determine the role of the released TNF-α in
activation of cPLA2α and of NF-κB by IFNγ, its auto-
crine effect was prevented by pre-incubation of the cells
with anti-TNF-α-neutralizing antibody before stimula-
tion. The presence of anti-TNF-α prevented the activa-
tion of cPLA2α as detected by its phosphorylated forms
on serine 505 (Fig. 6d) and prevented the activation of
NF-κB p-65 as detected by it phosphorylation on serine
536 (Fig. 6e) at 4 h of IFNγ stimulation. As shown in
Fig. 6f, the presence of anti-TNF-α prevented the induc-
tion of CD40 by IFNγ in the BV-2 microglia cells.
Addition of TNF-α alone to the cells did not induce
CD40 protein expression, as expected since both NF-kB
and STAT1 transcription factors are required for the in-
duction of CD40 by IFNγ, while TNF-α was shown to
activate only NF-κB that is located downstream to
STAT1α in the signal events [38].
Addition of IFNγ caused a rapid and significant (p <
0.0001) activation of STAT1α on either serine 727 or
tyrosine 701, detected at 15 min of activation (Fig. 7a,
b). Both phosphorylation were not affected by the pres-
ence of cPLA2α inhibitor, pyrrophenone, or the presence
of NOX2-NADPH oxidase inhibitor, DPI (Fig. 7c, d),
suggesting that STAT1α is not under cPLA2α regulationin the signal cascade leading to CD40 induction by IFNγ
in the BV-2 cells.
Discussion
The present study shows that cPLA2α is involved in the
induction of CD40 by either LPS or IFNγ. Reduction of
cPLA2α upregulation by a specific antisense or inhibition
of cPLA2α activity by a specific inhibitor prevented the
induction of CD40 protein expression by either LPS or
IFNγ. The results suggest that cPLA2α has a direct role
in CD40 upregulation, a feature of the pro-inflammatory
M1-phenotype. In accordance with this view, the regula-
tory role of cPLA2α in the induction of several charac-
ters of M1 phenotype in microglia and macrophages,
such as iNOS, COX2, NOX2-NADPH oxidase as well as
production of eicosanoids and pro-inflammatory media-
tors, was reported by us and others [40, 44]. cPLA2α,
however, is not involved in the transformation to M2-
phenotype, as its protein level was not elevated by
addition of IL4 + IL10, and the presence of AS did not
affect the significant induction of CD206 or of arginase
1 in microglia. In accordance with our results, it was re-
ported that the antiinflammatory cytokines IL4 or IL10
by themselves did not affect cPLA2α activation or bio-
synthesis [45, 46], further supporting the role of cPLA2α
in inflammatory processes.
The results of the present study show that superoxides
generated by NOX2-NADPH oxidase participate in up-
regulation of CD40 expression induced by LPS or IFNγ
in microglia, since inhibition of NOX-2 NADPH oxidase
prevented the induction of CD40. We show here that in
BV-2 microglia cell line, inhibition of the activation of
cPLA2α induced by either LPS or IFNγ, as demonstrated
Fig. 6 Endogenously produced TNF-α regulates cPLA2α activation in the BV2 cells under IFNγ stimulation. a A representative immunoblot analysis
of the kinetics of cPLA2α activation detected by its phosphorylated form induced by 10 ng/ml TNF-α in BV-2 microglia lysates. A representative
immunoblot analysis of a dose-dependent activation of the cPLA2α (b) and of NF-kB (c) detected by their phosphorylated induced by TNF-α in
BV-2 microglia lysates. Representative immunoblot analysis of (d) cPLA2α phosphorylation on Ser-505 and (e) NF-kB p-65 phosphorylation on
Ser-536 in unstimulated or stimulated BV-2 microglia by 10 ng/ml IFNγ for 4 h in the absence or presence of 2 μm pyrrophenone (Pyrro) or
50 ng/ml TNF-α-neutralizing antibody (anti-TNF-α) added to the cells 60 min before stimulation with IFNγ stimulation. The intensity of each p-
cPLA2α(Ser-505) or p-NFκB p65(Ser-536) band after quantification by densitometry was divided by the intensity of each cPLA2α or NFκB p65 band,
respectively, and expressed as arbitrary units. The results are the mean ± SE from four experiments. f Immunofluorescence analysis of CD40 protein
expression in unstimulated or stimulated BV-2 microglia with 10 ng/ml IFNγ for 24 h in the absence or presence of 50 ng/ml TNF-α-neutralizing
antibody or stimulated by 10 ng/ml TNF-α. Scale bars= 50 μm. The intensity of CD40 was quantitated and expressed in the bar graph as arbitrary units.
The bar graph is the mean ± SE from four independent experiments. DAPI staining shows cell nuclei. (***p < 0.0001, n.s. not significant)
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hibitor of cPLA2α activity, pyrrophenone, inhibited the
production of superoxides by the NOX2-NADPH oxi-
dase. Inhibition of the oxidase activity did not affect
cPLA2α activation detected by its phosphorylated form.These results suggest that the NOX2-NADPH oxidase is
regulated by cPLA2α in microglia stimulated with either
LPS or IFNγ, that is similar to ours and other studies re-
lated to the various phagocytic cells stimulated with a
variety of agonists [31, 40, 44, 47–50]. We show here
Table 1 TNF-α secretion induced by INFγ
Medium treated IFNγ treated (4 h)
0.06 ± 0.004 2.7 ± 0.05
Cells were treated with 10 ng/ml IFNγ
The results are means ± SED from three independent experiments
There is a significant difference between the treated and non-treated
cells (p < 0.0001)
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branes of activated microglia, where it binds p47phox
subunit of NOX2-NADPH oxidase, in accordance with
our previous studies in other phagocytic cells as well as
in primary rat microglia [40, 43, 48, 50]. The binding be-
tween p-cPLA2α and 47
phox was detected at 15 min
when the microglia cells were stimulated with LPS and
at 4 h when stimulated with IFNγ in correlation with the
detection of superoxide production and the kinetic of
cPLA2α phosphorylation by the two stimuli. Our previ-
ous study [43] demonstrated that arachidonic acid acti-
vated the assembled oxidase in activated cPLA2α-
deficient cells, although the precise mechanism is not
known. The restoration of CD40 upregulation in the ac-
tivated cells that were pretreated with AS against
cPLA2α by addition of arachidonic acid is probably due
to the activation of the NOX2-NADPH oxidase. TheFig. 7 cPLA2α or NADPH oxidase did not affect STAT1α activation under IF
STAT1α phosphorylation on (a) tyrosine 701 or (b) serine 727 induced by 1
phosphorylation on (c) tyrosine 701 or on (d) serine 727 in unstimulated o
or presence of 2 μm pyrrophenone (Pyrro) or 5 μm DPI (added to the cells
STAT1α (p-STAT1α) band was quantitated as described in Fig. 4. The Bar gr
not significant)activation of cPLA2α at 15 min by LPS and at 4 h by
IFNγ was mediated by ERK activation since the presence
of MEK inhibitor inhibited cPLA2α activation in accord-
ance with ours and other earlier studies [44, 51].
The involvement of two transcription factors, NF-κB
and STAT1α, was reported in the signal transduction
pathways leading to induction of CD40 by either LPS or
IFNγ [37–39]. While NF-κB was shown to be rapidly ac-
tivated by LPS, it was activated only at 4 h following ex-
posure to IFNγ. In contrast, STAT1α was rapidly
activated by IFNγ and only at 4 h by LPS. Time-
dependent activation of cPLA2α detected by its phos-
phorylation on serine 505 revealed that cPLA2α is rap-
idly activated by LPS and only considerably later (4 h) by
IFNγ, that is in accordance with a previous report [44].
We show in the present study that the kinetic of activa-
tion of cPLA2α coincided with the kinetic of NF-kB acti-
vation and that the activation of cPLA2α is required for
the activation of NF-κB in BV-2 microglia cell line, a
finding consonant with our earlier study in microglia ac-
tivated with amyloid beta [40]. While superoxide pro-
duction by NOX2-NADPH oxidase is extremely
important for killing invading pathogens, it is also an
important activator of diverse cell signaling pathways
such as mitogen activated protein kinase and NF-κB toNγ stimulation. A representative immunoblot analysis of the kinetics of
0 ng/ml IFNγ. A representative immunoblot analysis of STAT1α
r stimulated BV-2 microglia by 10 ng/ml IFNγ for 15 min in the absence
60 min before stimulation). The intensity of each phosphorylated
aphs are the mean ± SE from three experiments (***p < 0.0001, n.s.
Fig. 8 The involvement of cPLA2α in the proposed schematic NF-κB signaling pathways of CD40 protein expression induced by LPS or IFNγ
(described in the “Discussion”section)
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pro-inflammatory factors [40, 52, 53]. The activation of
NF-κB by either LPS or IFNγ shown in the present study
detected by the phosphorylation of its p-65 subunit on
serine 536 is probably mediated by superoxides pro-
duced by the NOX2-NADPH oxidase since the inhib-
ition of the oxidase activity prevented NF-kB action. In
line with this suggestion, the phosphorylation of p65
NF-kB RelA on Ser-536 is known to be redox-sensitive
[54]. The activation of NF-kB by NOX2-NADPH oxidase
activity is consistent with our previous studies in micro-
glia and macrophages [40, 55] and with other in various
systems and by various agonist [56, 57].
It was reported that the activation of NF-kB under
IFNγ stimulation is mediated by an autocrine effect of
released TNF-α from the stimulated cells [37]. Consist-
ent with this observation, we show here that the activa-
tion of cPLA2α and of NF-kB and the induction of
CD40 by IFNγ are mediated by an autocrine effect of
TNF-α, since TNF-α secretion from the activated cells
was detected and the levels of secreted TNF-α activated
cPLA2α and NF-kB. In addition, the presence of anti-
bodies against TNF-α in microglia stimulated with IFNγ
of all three processes were inhibited, suggesting that
cPLA2α activation by TNF-α regulates the induction of
CD40 via NF-kB activation. The activation of cPLA2α by
TNF-α coincided with other reports in microglia and
macrophages [46, 58]. However, addition TNF-α is not
sufficient to induce CD40, although it activates cPLA2α,
probably since it stimulates the activation of NF-κB but
not the activation of STAT1α that is also required for
CD40 induction.
The activation of cPLA2α and NF-κB in the signals
leading to CD40 upregulation by LPS is mediated byboth MyD88 and TRIF pathways, since inhibition of
each pathway inhibited cPLA2α and NF-κB activation
and abolished CD40 induction. In accordance with our
results, the activation of cPLA2α by MyD88 and by
TRIFF adaptive protein was shown in macrophages stim-
ulated by LPS [59]. The activation of NF-κB leading to
CD40 upregulation by LPS was suggested to be mediated
only by MyD88 adaptive protein in macrophages [39].
However, several studies reported, similar to our results,
that both pathways are mediating NF-κB by TLR4 recep-
tor in macrophages and other cell types [59–61].
Conclusions
Our results show for the first time that cPLA2α regulates
CD40 protein induction in microglia by either LPS or IFNγ,
and this regulation is mediated via activation of NOX2-
NADPH oxidase and NF-κB. STAT1α transcription factor,
that was reported to participate in CD40 induction, was early
activated by IFNγ and late activated by LPS as detected by
the phosphorylation on either serine 727 or tyrosine 701,
but this activation was not under cPLA2α regulation. As
shown in Fig. 8, cPLA2α is located in the early event induced
by LPS and its activation is mediated by both adaptor pro-
teins, TRIF and MyD88. While, under IFNγ stimulation,
cPLA2α is activated at a later time (4 h) by the autocrine ef-
fect of released TNF-α. Under both stimuli, cPLA2α activa-
tion is mediated by ERK activity. The role of cPLA2α in the
induction of the CD40 suggests that cPLA2α may serve as
an amplifier of the inflammatory response in the CNS and
the reduction of its levels in the inflamed organ can lead to
therapeutic effect.
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